DEF 14A: Precigen Seeks Shareholder Approval for Incentive Plan Amendment, Director Elections and Executive Pay

Precigen is asking shareholders to vote on key proposals at its upcoming annual meeting, including an amendment to its incentive plan, the election of directors, and executive compensation.

Summary

• Precigen, Inc. is holding its 2024 Annual Meeting of Shareholders on July 5, 2024, in a virtual format.
• Shareholders will vote on several proposals, including the election of nine directors, ratification of Deloitte & Touche LLP as the independent accounting firm, approval of executive compensation, and an amendment to the 2023 Omnibus Incentive Plan to increase the number of shares available by 2 million.
• The Board of Directors recommends voting 'FOR' all proposed nominees and proposals.
• The record date for determining shareholders eligible to vote is May 3, 2024.
• The Board has nominated Nancy Howell Agee for election as a new director, while Dean Mitchell will be retiring at the Annual Meeting.
• The company is seeking approval to increase the number of shares available under the 2023 Omnibus Incentive Plan by 2 million shares.
• The Board believes this increase is necessary to attract, motivate, and retain key personnel.
• The company's three-year average burn rate is 2.7%, and the overhang percentage is 15.6% as of May 15, 2024.
• If the amendment is approved, the overhang percentage would increase to approximately 16.4%.

Sentiment

Score: 7

Explanation: The document is neutral in tone, presenting factual information about the upcoming shareholder meeting and proposals. The sentiment is slightly positive due to the company's efforts to attract and retain talent and manage its equity compensation plan effectively.

Positives

• The Board is actively seeking to attract and retain talent through equity-based compensation.
• The company is committed to managing its share reserves effectively.
• The company has implemented corporate governance best practices in its equity compensation plan, such as minimum vesting requirements and a prohibition on repricing options without shareholder approval.

Negatives

• The proposed amendment will increase the potential dilution for existing shareholders, with the overhang percentage rising to approximately 16.4% if approved.

Risks

• If the amendment to the 2023 Omnibus Incentive Plan is not approved, the company may face challenges in attracting and retaining key personnel.
• The company's future share usage could be impacted by various factors, such as hiring activity, stock price performance, and potential acquisitions or dispositions.

Future Outlook

The company seeks to attract, motivate, and retain the most competent and skilled officers, employees, non-employee directors, and other service providers, which is a significant factor for our long-term success.

Management Comments

• The Board believes the number of shares underlying the Plan represents a reasonable amount of potential additional equity dilution, and is committed to effectively managing our share reserves for equity compensation while minimizing stockholder dilution.

Industry Context

The document relates to corporate governance matters common to publicly traded companies, particularly those in the biotechnology sector, where equity compensation is a key tool for attracting and retaining talent.

Comparison to Industry Standards

• The document mentions that the Compensation Committee reviews compensation based on market practice information provided by an outside compensation consultant.
• The peer analysis conducted by Aon considered our peer companies to be U.S. based biotechnology companies predominantly in Phase I/II clinical trials with some Phase III companies, market capitalization of $100 million to $1.4 billion and a headcount of 75 to 625 employees.
• These companies generally specialize in oncology, gene and/or cell therapy, vaccine development and/or a diverse portfolio with one or more of the specialties.

Management Changes

Related Party Transactions

• In January 2023, an affiliate of Mr. Kirk, RJ Kirk Trust, purchased 11.4 million shares at the public offering price of $1.75 for an aggregate purchase price of approximately $20.0 million, through the underwriters.
• J.P. Morgan Securities LLC, where Mr. Frank currently serves as Chairman of Global Healthcare Investment Banking, acted as a representative to the several underwriters in the offering and received underwriting commissions of $2.56 million.

Stakeholder Impact

• Shareholders: The proposals directly impact shareholders through voting rights, potential dilution, and the company's ability to attract and retain talent.
• Employees: The incentive plan amendment affects employees' compensation and motivation.
• Customers: The company's ability to attract and retain talent can indirectly impact the quality of products and services offered to customers.

Next Steps

• Shareholders will vote on the proposals at the Annual Meeting on July 5, 2024.
• The company will file a registration statement on Form S-8 with the SEC if the amendment to the 2023 Omnibus Incentive Plan is approved.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Shareholders, Board of Directors, Director Election, Executive Compensation, Incentive Plan, Equity Compensation, Deloitte & Touche, Corporate Governance